RMDN2

Across TCGA pan-cancer cohorts, RMDN2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RMDN2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RMDN2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated RMDN2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

CCRCC, LUAD, and HNSC are the cancer types where RMDN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.156	0.757	.038	10	view →
LUAD	DFS	Median	III,IV	0.504	0.977	.005	9	view →
HNSC	DFS	Median	II,III,IV	0.899	0.991	.005	8	view →
PDAC	DFS	Median	III,IV	0.548	0.164	.002	7	view →
LSCC	DFS	Median	II,III,IV	0.540	0.851	.009	6	view →
UCEC	DFS	Median	All	0.918	0.787	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RMDN2–CCRCC (DFS)

Open the CCRCC breakdown →